平均随访8.2年，共有554名参与者出现致死性和非致死性心血管事件，包括心肌梗死、卒中、冠心病和心力衰竭。
Over an average of 8.2 years of follow-up, 554 participants experienced fatal and nonfatal cardiovascular events, including myocardial infarction, stroke, coronary artery disease, and heart failure.
主要终点比较心血管不良事件，这些事件包括病人死亡的首要原因、非致死的心肌梗死、非致死的脑卒中。
Main outcome Measures Adverse cardiovascular outcomes, including the primary outcomes which was the first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke.
结论在近期有过一次急性冠脉综合征的患者中，利伐沙班降低了包括心血管原因所致死亡、心肌梗死或卒中的复合终点的发生危险。
CONCLUSIONS in patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke.
非ami组包括健康人80例及陈旧心肌梗死、心绞痛、肾衰等患者。
Non AMI group included 80 normal subjects, patients with old myocardial infarction, angina pectoris, renal failure and so on.
房颤(AF)是最常见的心律失常，严重并发症包括充血性心衰、心肌梗死和血栓栓塞。
Atrial fibrillation (AF) is the most common arrhythmia. Serious complications include congestive heart failure, myocardial infarction and thromboembolism.
急性冠脉综合征(ACS)包括不稳定心绞痛(UA)、非st段抬高心肌梗死(NSTEMI)和ST段抬高心肌梗死(STEMI)。
Acute coronary syndrome (ACS) includes unstable angina (UA), non-ST segment elevated myocardial infarction (NSTEMI) and st segment elevated myocardial infarction (STEMI).
目的明确吸入抗胆碱能药物发生心血管不良反应(包括心血管病死亡，心肌梗死以及卒中)的危害。
Objective To ascertain the cardiovascular risks of inhaled anticholinergics, including cardiovascular death, myocardial infarction (MI), and stroke.
方法：采用病例对照研究，包括10 0例心肌梗死患者及110例具有相同民族的对照人群；
METHODS: A case control study including 100 patients and 110 controls of the same race was performed.
随访包括死亡，心肌梗死，脑卒中和再次血运重建等主要不良心脑血管事件(MACCE)。
Follow up main adverse cardiovascular and cerebrovascular events (MACCE) such as death, myocardial infarction, stroke and repeated revascularization.
30天和一年的住院期间，其主要结局是缓慢流动/无复流现象（SF-NR）的发生，临床终点包括死亡、心肌梗死（MI）、靶病变血管血运重建术（TVR）和主要心脏不良事件（MACE）。
The primary outcome was the occurrence of SF-NR Clinical endpoints included death, MI, target vessel revascularization (TVR), and MACE during the hospitalization period, 30 days and at 1 year.
30天和一年的住院期间，其主要结局是缓慢流动/无复流现象（SF-NR）的发生，临床终点包括死亡、心肌梗死（MI）、靶病变血管血运重建术（TVR）和主要心脏不良事件（MACE）。
The primary outcome was the occurrence of SF-NR Clinical endpoints included death, MI, target vessel revascularization (TVR), and MACE during the hospitalization period, 30 days and at 1 year.
应用推荐